Ianalumab plus Eltrombopag in Immune Thrombocytopenia
New England Journal of Medicine · 16.04.2026 · 394 (15) · 1503-1513
DOI: 10.1056/nejmoa2515168 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 16.04.2026. Verfasst von Adam Cuker und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Benzoates, Hydrazines, Purpura, Thrombocytopenic, Idiopathic. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Novartis.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine and Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
- Department of Internal Medicine II, Hematology and Oncology, University Hospital Jena, Jena, Germany.
- Centre for Haematology, Department of Immunology and Inflammation, Imperial College, London.
- Division of Hematology Oncology, Massachusetts General Hospital, Harvard Medical School, Boston.
- Department of Internal Medicine, Henri Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Est Créteil University, Créteil, France.
- Østfold Hospital Trust, Kalnes, Norway.
ORCID-Profile: Hanny Al-Samkari
Förderung
- Novartis
Zitieren
APA
Cuker, A., Stauch, T., Cooper, N., Al-Samkari, H., Michel, M., Ghanima, W., Urban, P., Fronczek, J., Foster, M., Weill, M., Zhang, L., Hou, M., Zander, T., Sharif, A., Sun, J., Nath, U. K., Schutgens, R., Rossi, E., Deleu, L., …, & VAYHIT2 Investigators (2026). Ianalumab plus Eltrombopag in Immune Thrombocytopenia. New England Journal of Medicine, 394(15), 1503-1513. https://doi.org/10.1056/nejmoa2515168
Vancouver
Cuker A, Stauch T, Cooper N, Al-Samkari H, Michel M, Ghanima W, et al. Ianalumab plus Eltrombopag in Immune Thrombocytopenia. New England Journal of Medicine. 2026;394(15):1503-1513. doi:10.1056/nejmoa2515168
BibTeX
@article{Cuker2026,
author = {Cuker, Adam and Stauch, Thomas and Cooper, Nichola and Al-Samkari, Hanny and Michel, Marc and Ghanima, Waleed and Urban, Patrick and Fronczek, Justyna and Foster, Matthew and Weill, Marine and Zhang, Lei and Hou, Ming and Zander, Thomas and Sharif, Azizan and Sun, Jing and Nath, Uttam Kumar and Schutgens, Roger and Rossi, Elena and Deleu, Lien and Červinek, Libor and Yoon, Jae-Ho and Chang, Hung and Ruchutrakool, Theera and Iino, Masaki and Goto, Tatsunori and Zaja, Francesco and VAYHIT2 Investigators, VAYHIT2 Investigators},
title = {Ianalumab plus Eltrombopag in Immune Thrombocytopenia},
journal = {New England Journal of Medicine},
year = {2026},
volume = {394},
number = {15},
pages = {1503--1513},
doi = {10.1056/nejmoa2515168}
}
EUVIMED